The Board of Kintor Pharmaceutical Limited announced that Mr. Ming Ming CHEUNG, the vice president of investment and overseas business of the Group, has been appointed as the chief financial officer of the Company with effect from 14 April 2023. Mr. Cheung will be primarily responsible for the financial planning, investment, international commerce, internal control, investor relations and public relations of the Group. In light of Mr. Cheung's new role as the CFO, Mr. Cheung has ceased to act as the vice president of investment and overseas business with effect from 14 April 2023.

Mr. Cheung, aged 46, joined the Group in September 2021 as the vice president of investment and overseas business of the Group. Mr. Cheung has over 15 years' of work experience in the capital market. Prior to joining the Group, he was Head of Leveraged & Acquisition Finance of Haitong International Securities Group Limited.

He was in charge of leveraged acquisition finance and equity fund investments respectively. Mr. Cheung also worked in ING Bank Hong Kong Branch for over 5 years. He was responsible for corporate client coverage and merger and acquisition financial advisory.

Mr. Cheung obtained his bachelor's degree in Biochemistry from the Hong Kong University of Science and Technology in 1999 and Master of Philosophy in Bioinformatics from Medical School, the University of Hong Kong in 2002. Ms. Yan LU tendered her resignation as the CFO of the Company with effect from 13 April 2023 to pursue her personal endeavours.